Added to YB: 2025-09-29
Pitch date: 2025-09-25
HROW [bullish]
Harrow, Inc.
+4.56%
current return
Author Info
MMMT Wealth is a CPA who shares stock pitches in their newsletter. Sign up for the newsletter.
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.8B
Pitch Price
$46.29
Price Target
231.00 (+390%)
Dividend
N/A
EV/EBITDA
59.46
P/E
-167.77
EV/Sales
8.55
Sector
Pharmaceuticals
Category
growth
Harrow (HROW): High Growth Outside Tech
HROW: Ophthalmic pharma w/ FDA-approved drugs (VEVYE, IHEEZO, TRIESENCE) + compounding division. Mgmt targets $1B revenue by 2027 vs analyst est. $529M. Current 5.9x NTM sales, 19.9x EBITDA despite 36-88% revenue CAGR potential. Key risks: rebate pressure from PBMs, execution complexity across multiple verticals.
Read full article (9 min)